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The breakdown of cellular fat stores fuels energy production and multiple anabolic processes. Albert et al.
(2014) demonstrate that the lack of hormone-sensitive lipase, a member of the enzyme trio that catabolizes
fat, has pronounced effects on lipid metabolism, glucose homeostasis, and cell signaling in humans.Adipose tissue is the body’s largest
reservoir of energy and a major source
of metabolic fuel. In periods of food sup-
ply, excess nutrients are stored as triglyc-
erides (TGs) in white adipose tissue,
whereas during energy demand, TGs
are hydrolyzed to release nonesterified
fatty acids (FAs) into the bloodstream.
Nonadipose tissues, in turn, utilize FAs
effectively for energy production, mem-
brane lipid synthesis, or lipid signaling.
The transient storage of FAs as TGs in
adipose tissue is also important to pro-
tect the organism from harmful ‘‘lipo-
toxic’’ effects of excessive intracellular
FA concentrations including ectopic lipid
deposition in liver and skeletal muscle
and the development of insulin resis-
tance. Thus, alterations in adipose tissue
TG metabolism have profound effects on
whole-body homeostasis. The catabolic
pathway hydrolyzing TGs is called lipol-
ysis. It is an exquisitely controlled pro-
cess involving a variety of cell-surface re-ceptors, neurotransmitters, hormones,
and paracrine factors that result in the
sequential enzymatic hydrolysis of three
FA-glycerol ester bonds (Lafontan and
Langin, 2009; Zechner et al., 2012). The
major enzymes working in a step-wise
fashion are adipose triglyceride lipase
(ATGL), hormone-sensitive lipase (HSL),
and monoglyceride lipase (MGL). Mouse
and human studies identified ATGL as
the major TG lipase, while HSL and
MGL predominantly hydrolyze diglycer-
ides (DGs) and monoglycerides (MGs),
respectively. HSL has a broader sub-
strate specificity than the other enzymes
additionally hydrolyzing TGs, MGs, retinyl
esters (REs), and cholesterol esters
(CEs). The phenotypes observed in
lipase-deficient mouse models are
consistent with these enzymatic activ-
ities. ATGL-deficient mice accumulate
TGs in multiple tissues with the highest
fat content in oxidative tissues such as
brown adipose tissue, cardiac muscle,and kidney. Loss of ATGL in cardiac mus-
cle results in severe cardiomyopathy,
heart failure, and premature death in
ATGL knockout mice at the age of
4 months. In humans, ATGL deficiency
causes neutral lipid storage disease with
myopathy (NLSDM) (Fischer et al.,
2007), a condition similar to the knockout
phenotypes observed in mice. Clinical
manifestations start later and are more
variable in humans than in mice, but
many patients also develop a severe
cardiomyopathy requiring heart trans-
plantation to prevent cardiac death.
Despite a very detailed knowledge
of the biochemical and physiological
functions of HSL, a clear link between
HSL deficiency and human disease was
missing. Now, Albert et al. (2014) report
in the June 12 issue of the New England
Journal of Medicine the first clinical
characterization of individuals with a
frameshift mutation in the LIPE gene
encoding HSL (Albert et al., 2014).0, August 5, 2014 ª2014 Elsevier Inc. 199
Figure 1. Consequences of the Lack of Functional Hormone-
Sensitive Lipase (HSL) in Carriers of a Frameshift Mutation of the
LIPE Gene
Through hydrolysis of diglycerides (DGs), retinyl esters (REs), or other un-
known substrate, HSL provides yet unidentified ligand(s) for peroxisome pro-
liferator-activated receptor-g (PPARg) and/or retinoid-X receptor-a (RXRa),
which act as heterodimers and are essential transcription factors for adipo-
genesis and lipid synthesis. As the capacity of storage in fat is limited, circu-
lating fatty acids (FAs) are shunted to the liver favoring ectopic lipid deposition
and promoting metabolic complications leading to dyslipidemia and diabetes.
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PreviewsA 19 bp deletion in the last
exon results in the addition
of 86 amino acids to the C
terminus of the protein. The
mutation leads to lower
abundance of HSL protein
in adipose tissue of carriers
(50% in heterozygotes,
100% in homozygotes)
due to either decreased en-
zyme synthesis or increased
turnover. Subcutaneous adi-
pose tissue from a homozy-
gous carrier exhibited drasti-
cally decreased basal and
stimulated glycerol release
consistent with a defect in




HSL expression in carriers
are less pronounced than in
NLSDM and resemble in
some but not all aspects
the phenotype observed inHSL-deficient mice (Osuga et al., 2000).
Both humans and mice are not obese
and develop partial lipodystrophies with
age. Reduced peroxisome proliferator-
activated receptor (PPAR)-g signaling
in adipose tissue leads to decreased
adipogenesis, lipogenesis, and lipid
synthesis. These findings by Albert and
colleagues are important because they
provide compelling evidence for an
essential involvement of HSL-mediated
lipolysis in cellular signaling processes
also in humans. The data support earlier
proposals from mouse studies that the
HSL reaction provides ligands to activate
the central adipogenesis transcription
factors PPARg and/or retinoid-X receptor
(RXR)-a (Strom et al., 2009; Zimmermann
et al., 2003). Together with the recent
finding that ATGL-mediated lipolysis is
essential for PPARa signaling in cardiac
muscle (Haemmerle et al., 2011), these
data underline the general importance
of lipolysis for the regulation of gene
transcription by nuclear receptors. Inter-
estingly, the impairment of adipogenesis
in humans with the HSL mutation ex-
hibits site specificity; certain fat depots
are affected (e.g., subcutaneous fat in
different locations), while others are not
(e.g., visceral fat).
In addition to common findings in mice
and humans with defects in HSL-medi-200 Cell Metabolism 20, August 5, 2014 ª201ated lipolysis, several notable differences
were also observed. (1) Unlike male HSL-
deficient mice, a male homozygous
carrier of the HSL mutation has offspring.
The mechanisms underlying these
differences in fertility are unknown but
may imply species-specific differences
in the role of HSL in spermatogenesis.
(2) Despite decreased lipolytic rates,
homozygous carriers have increased
liver fat, increased plasma TG concen-
trations, and decreased plasma HDL.
This is in sharp contrast to the phenotype
described for HSL-deficient mice, where
the lipolytic defect leads to reduced FA
transport to the liver, decreased liver fat,
decreased VLDL synthesis, lower plasma
TG, and increased plasma HDL. The dif-
ferences may be explained by the fact
that lipid and lipoprotein parameters
were analyzed at an age when the
adipose tissue of human HSL mutation
carriers already exhibited diminished
lipid storage capacity (due to decreased
PPARg signaling), leading to ectopic
fat accumulation and hepatosteatosis
(Figure 1). In contrast, HSL-knockout
mice were analyzed at a younger age
when the fat storage function of white
adipose tissue was relatively normal
and ectopic lipid accumulation did not
occur. Other explanations include the
possibility that hepatic HSL affects lipid4 Elsevier Inc.and lipoprotein metabolism
differently in humans and
mice. (3) The most noticeable
differences between humans
and mice with defective HSL
were observed with regard
to glucose metabolism. In
contrast to HSL-deficient
mice, which are nondiabetic,
all four homozygous carriers
investigated by Albert et al.
developed diabetes. The
authors convincingly reason
that the partial lipodystrophy
in these patients may lead to
insulin resistance and type 2
diabetes. However, the small
number of affected patients
and a potential impact of en-
vironmental/behavioral effects
in these individuals require
confirmation of a role of HSL
the pathogenesis of diabetes
in a larger study group.
The interpretation of the
phenotype of heterozygouscarriers is more challenging. Compared
to noncarriers, these individuals show
very modest changes in blood lipid pro-
files and fasting plasma glucose concen-
trations but display a marked decrease
in glucose tolerance and a higher risk of
type 2 diabetes. This is the opposite
finding to what was reported for haploin-
sufficient mice with only one intact allele
of Lipe and a comparable decrease in
HSL protein abundance in adipose tissue
(50%) (Girousse et al., 2013). These
mice exhibit improved tissue and whole-
body insulin sensitivity and increased
glucose tolerance. Similarly, chronic
treatment of wild-type mice with an HSL
inhibitor improved insulin sensitivity in
mice. Also in humans, a negative relation-
ship between fat cell lipolysis and insulin
sensitivity has been reported (Arner and
Langin, 2014; Girousse et al., 2013). How
can these results be reconciled with
decreased insulin sensitivity in heterozy-
gous carriers of the frameshift mutation
in the human LIPE gene? Unlike haploin-
sufficient mice, heterozygous carriers
show intact adipocyte lipolysis and no
evidence for an accumulation of the
major HSL substrates (DGs, CEs, and
REs) in adipose tissue. Therefore, it is
conceivable that the presence of the
enzymatically inactive mutant protein
provokes metabolic effects by unknown
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Previewsmechanisms that differ from those ob-
served in mice with defective lipolysis.
Taken together, the work by Albert
et al. underlines the key role of HSL for lipid
metabolism, energy homeostasis, and cell
signaling in humans. Important questions,
however, remain open: Which lipolytic
mediators are involved in the regulation
of gene transcription by nuclear recep-
tors? What are the (species-specific)
mechanistic links between HSL deficiency
insulin resistance and diabetes? What is
the molecular basis for hepatosteatosis
and dyslipidemia in humans lacking HSL?
Additional studies in humans and mice
with HSL deficiency will answer these
questions.
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The insulin-degrading enzyme (IDE) has been identified as a type 2 diabetes and Alzheimer’s disease
susceptibility gene, though its physiological function remains unclear. Maianti et al. (2014) now propose
that an IDE inhibitor may be a promising therapeutic strategy for type 2 diabetes.Insulin-degrading enzyme (IDE) is a high-
ly conserved and widely expressed Zn2+
metalloprotease first identified through
its action to degrade insulin. IDE also
degrades a variety of substrates that
share in common small size (<50 amino
acids) and a pattern of charged and
hydrophobic residues rather than being
from a particular family of proteins
(Shen et al., 2006). Interest in IDE func-
tion was prompted by genome-wide as-
sociation studies that suggested linkage
to IDE for both type 2 diabetes (Sladek
et al., 2007) and Alzheimer’s disease
(Bertram et al., 2000), although linkage
to the former has not always been repli-cated. Whether the genetic linkage of
IDE with type 2 diabetes and Alzheimer’s
disease is due to loss or gain of function
of IDE enzyme activity also remains
unclear, though investigators in the
Alzheimer’s disease field have concluded
that inactivation of IDE underlies the as-
sociation (Farris et al., 2004). Loss of
function of IDE has also been implicated
in pancreatic b cell failure, as the Ide/
mouse has impaired insulin secretion
(Steneberg et al., 2013), and an inactivat-
ing mutation in the Ide gene is respon-
sible for failed insulin secretion in the
Goto-Kakizaki (GK) rat model of type 2
diabetes (Farris et al., 2004). Moreover,genetic analysis of type 2 diabetes sus-
ceptibility variants linked the IDE gene
to impaired insulinogenic index, a dia-
betic trait that is a measure of insulin
secretion (Dimas et al., 2014). In a recent
intriguing Nature paper, Maianti et al.
(2014) propose that acute inhibition of
IDE activity may be a novel therapeutic
approach to restore postprandial hyper-
glycemia in type 2 diabetes (Maianti
et al., 2014).
Maianti et al. (2014) performed an
impressive chemical and biochemical
survey in order to select an optimal
small-molecule modulator of IDE. After
establishing ideal arrangements of the0, August 5, 2014 ª2014 Elsevier Inc. 201
